Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 12/20 | 0.42 |
| ▸ | TACR1 | P25103 | 8/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6990714 | 0.85 | TACR1 (0.57) | GPBAR1TACR1 | |
| SCHEMBL6990538 | 0.79 | TACR1 (0.59) | GPBAR1TACR1 | |
| SCHEMBL14514048 | 0.78 | TACR1 (0.44) | GPBAR1TACR1 | |
| SCHEMBL6986187 | 0.77 | TACR1 (0.52) | GPBAR1TACR1 | |
| SCHEMBL6988382 | 0.76 | TACR1 (0.48) | GPBAR1TACR1 | |
| SCHEMBL6991745 | 0.75 | TACR1 (0.57) | GPBAR1TACR1 | |
| SCHEMBL7522146 | 0.74 | TACR1 (0.60) | GPBAR1TACR1 | |
| SCHEMBL6985139 | 0.70 | TACR1 (0.49) | GPBAR1TACR1 | |
| SCHEMBL6988800 | 0.69 | TACR1 (0.57) | GPBAR1TACR1 | |
| SCHEMBL6983809 | 0.69 | TACR1 (0.57) | GPBAR1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489083-B1 | FUSED BICYCLIC PYRIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | KYORIN SEIYAKU KK (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-7030107-B2 | nitrogen compounds such as 5-[3,5-bis(trifluoromethyl)benzyl]-6-oxo-7-phenyl-9-[4-(pyrrolidine-1-yl)piperidine-1-yl]-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine, used as neurokinin inhibitors for prophylaxis of urogenital disorders; side effect reduction | KYORIN PHARMACEUTICAL.CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7026309-B2 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20050107375-A1 | Fused bicyclic pyridine derivatives as tachykinin receptor antagonists | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| US-20050101591-A1 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1489083-A1 | FUSED BICYCLIC PYRIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1457493-A1 | FUSED BICYCLIC PYRIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107375-A1 | Fused bicyclic pyridine derivatives as tachykinin receptor antagonists | BDKRB1, BDKRB2, TACR1 | GPBAR1 373/4885TACR1 3/4885 |
| US-20050101591-A1 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | BDKRB1, BDKRB2, NPY1R | GPBAR1 179/4885TACR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.